Dallas-Fort Worth Life Sciences – BioTech Guide
  • Home
  • Ecosystem
  • Business Case
  • News
    • Relocations & Expansions
    • Investments
  • Contact
Tag:

biotech

  • NEWS

    New CEO at Biotech, Gradalis

    by ddankesreiter@dallaschamber.org January 16, 2026
    by ddankesreiter@dallaschamber.org January 16, 2026

    Carrollton-based Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, has named Steven D. Weinstein as its new chief executive officer. Weinstein brings more than 20 years as a …

    0 FacebookTwitterPinterestEmail
  • NEWS

    New Biomanufacturing Training and Research Hub

    by ddankesreiter@dallaschamber.org January 13, 2026
    by ddankesreiter@dallaschamber.org January 13, 2026

    UTA and the Texas A&M Engineering Experiment Station have opened a new biomanufacturing training and research hub at Pegasus Park focused on workforce training and early-stage biotech development. The National …

    0 FacebookTwitterPinterestEmail
  • INVESTMENT

    Dallas Biotech Raises $40M for ‘Whole-Body Intelligence’ 

    by ddankesreiter@dallaschamber.org November 12, 2025
    by ddankesreiter@dallaschamber.org November 12, 2025

    Curve Biosciences founder and CEO, Plano-born Ritish Patnaik, says “chronic diseases are on the rise, and healthcare costs are skyrocketing as a result.” From its newly established HQ at Pegasus …

    0 FacebookTwitterPinterestEmail
  • NEWS

    NTX Biotech Preps for Rare Pediatric Brain Cancer Trial

    by ddankesreiter@dallaschamber.org October 31, 2025
    by ddankesreiter@dallaschamber.org October 31, 2025

    Lantern Pharma Inc. (Nasdaq: LTRN) said it plans to launch a clinical trial in early 2026 for a rare pediatric brain cancer, following what it called an “optimistic meeting” with the …

    0 FacebookTwitterPinterestEmail
  • INVESTMENTNEWS

    Where Computer Science Meets Life Science

    by ddankesreiter@dallaschamber.org September 12, 2025
    by ddankesreiter@dallaschamber.org September 12, 2025

    University of Texas at Arlington computer science professor, Junzhou Huang, has secured $3.1 million in federal funding to tackle one of medicine’s most time-consuming challenges: figuring out which antibodies will …

    0 FacebookTwitterPinterestEmail
  • NEWS

    Dallas Biochemist wins Prestigious Award

    by ddankesreiter@dallaschamber.org September 12, 2025
    by ddankesreiter@dallaschamber.org September 12, 2025

    UT Southwestern professor of biochemistry Steven McKnight, along with Dirk Görlich of the Max Planck Institute for Multidisciplinary Sciences in Germany, won the 2025 Albert Lasker Basic Medical Research Award …

    0 FacebookTwitterPinterestEmail
  • INVESTMENT

    Dallas Healthcare Accelerator Gets National Recognition

    by ddankesreiter@dallaschamber.org September 11, 2025
    by ddankesreiter@dallaschamber.org September 11, 2025

    Nationally ranked healthcare accelerator Health Wildcatters has named 11 startups to its newest class, marking what the Dallas-based program called another milestone in the region’s rise as a health innovation …

    0 FacebookTwitterPinterestEmail
  • NEWS

    India-based pharma company to bring U.S. HQ to Mansfield

    by ddankesreiter@dallaschamber.org August 26, 2025
    by ddankesreiter@dallaschamber.org August 26, 2025

    Mansfield Economic Development Corp. and Stallion Labs, whose headquarters is in Ahmedabad, struck a deal on an economic incentive and performance agreement, which was approved and the council July 14. …

    0 FacebookTwitterPinterestEmail
  • NEWS

    Dallas Biotech’s new Tool Could Bring ‘Paradigm Shift’

    by ddankesreiter@dallaschamber.org August 25, 2025
    by ddankesreiter@dallaschamber.org August 25, 2025

    Only a small fraction of drugs can cross the blood-brain barrier–the layer that protects the brain from harmful substances. Usually a good thing, it also makes it harder to treat …

    0 FacebookTwitterPinterestEmail
  • INVESTMENTNEWS

    $30M Merger Creates Next-Gen #Biotech Company

    by ddankesreiter@dallaschamber.org August 25, 2025
    by ddankesreiter@dallaschamber.org August 25, 2025

    A $30 million merger among Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics has formed McKinney-based OSPRI, a next-generation biotechnology company and “one of the world’s …

    0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Opsin Biotherapeutics Awarded $2.35 Million NIH Grant to Advance Optogenetic Neuromodulation for Chronic Pain
  • Verily Health Selected to Build Data Platform for ARPA-H CIRCLE Program
  • UTSW receives ARPA-H award to create functioning artificial liver: Newsroom – UT Southwestern, Dallas, Texas
  • MusiQ Bio Lands $2.6M CPRIT Grant for Cancer Immunotherapy
  • MassChallenge Deepens Dallas Commitment with LHP

Recent Comments

No comments to show.

Social Connect

Facebook Twitter Instagram Pinterest Linkedin Youtube

Recent Posts

  • Opsin Biotherapeutics Awarded $2.35 Million NIH Grant to Advance Optogenetic Neuromodulation for Chronic Pain

  • Verily Health Selected to Build Data Platform for ARPA-H CIRCLE Program

  • UTSW receives ARPA-H award to create functioning artificial liver: Newsroom – UT Southwestern, Dallas, Texas

  • MusiQ Bio Lands $2.6M CPRIT Grant for Cancer Immunotherapy

  • MassChallenge Deepens Dallas Commitment with LHP

Categories

  • INVESTMENT (91)
  • NEWS (74)
  • RANKING (4)
  • RELOCATION (24)
  • Uncategorized (10)

CONTACT US

The Dallas Regional Chamber's Economic Development team serves as a single point of contact for companies, site selection consultants and corporate real estate executives examining the region for new and expanding companies.

  • Home
  • Ecosystem
  • Business Case
  • News
    • Relocations & Expansions
    • Investments
  • Contact
Dallas-Fort Worth Life Sciences – BioTech Guide
  • Home
  • Ecosystem
  • Business Case
  • News
    • Relocations & Expansions
    • Investments
  • Contact
  • Home
  • Ecosystem
  • Business Case
  • News
    • Relocations & Expansions
    • Investments
  • Contact